Audit: QRS - Avocado Oil for Health & Longevity

Audit conducted on 27/09/2026 11:19 using AI4L + evidence-mcp / Grok 4.1

Iterations

Summary

Items Count
Total 94
Passed 89
Failed 0
N/A 5
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢  
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢  
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢  
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢  
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢  
1.6 The QRS does not introduce new attributions. 🟢  

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢  
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢  
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢  
2.4 The QRS avoids language that implies medical or clinical advice 🟢  
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢  
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢  
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢  
2.8 Information is presented in a concise and very compact manner 🟢  
2.9 It DOES NOT address the reader directly 🟢  
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢  
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢  
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢  
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢  
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢  
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. 🟢  

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified:
* Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”
* Gate headings: “Contraindications”, “Key Interactions”
* Tier labels: “High”, “Medium”, “Low”, “Speculative”
* Table column headers in Monitoring: “Marker”, “Target”, “Why”
🟢  
3.2 All “…” from the [qrs_template] are present in the the QRS. 🟢  
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢  

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” 🟢  
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢  
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢  
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢  
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢  

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢  
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢  
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢  
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢  
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢  
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢  
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢  
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢  
5.9 The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) 🟢  
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢  
5.11 The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) 🟢  
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢  
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢  

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢  
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢  
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢  
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢  
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢  

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence 🟢  
7.2 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢  
7.3 [at_a_glance] is no longer than 70 words 🟢  
7.4 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢  
7.5 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢  
7.6 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢  
7.7 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢  

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢  
8.2 [stop_items] represent the Contraindications from the ER 🟢  
8.3 Individual [stop_items] are formatted as <li></li> 🟢  
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢  
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢  
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. 🟢  
8.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. 🟢  
8.8 If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A The contraindications list is not empty; it names the prior avocado-allergy population.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢  
9.2 [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications 🟢  
9.3 Individual [caution_items] are formatted as <li></li> 🟢  
9.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢  
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢  
9.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. 🟢  
9.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. 🟢  
9.8 If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A The key-interactions list is not empty; the ER lists six interactions.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢  
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢  
10.3 If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A The ER protocol states at least three actionable implementation aspects, so no action set is unused.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢  

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢  
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢  
11.3 If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A The ER states three time-to-effect aspects, so no time set is unused.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢  
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A The ER Practical Considerations section gives time-to-effect information, so the block stays in the protocol panel.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢  
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢  
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢  
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢  
12.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢  

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢  
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢  
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢  
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢  
13.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢  

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢  
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢  
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢  

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢  
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢  

Issues 27/09/2026 11:19

Pass rate 100.00%. No issues found.

Issues 27/09/2026 10:57

  1. 9.4 — Case-report study detail: The vitamin K antagonist bullet in Key Interactions (line 547) keeps “in case reports” after the INR finding. That is a study detail; the key fact is that avocado fruit lowered INR and the oil was not studied.

Fixes 27/09/2026 10:57

  1. 9.4 — Case-report study detail: Removed “in case reports” from the vitamin K antagonist interaction, leaving the INR drop and that the oil was not studied.

Issues 27/09/2026 10:53

  1. 1.2 / 1.3 — INR case-report caveat: The warfarin interaction (QRS line 547) drops “in case reports” from the ER bullet (line 236), so “avocado fruit lowered INR” reads as an unqualified fact rather than a case-report finding.

Fixes 27/09/2026 10:53

  1. 1.2 / 1.3 — INR case-report caveat: Restored “in case reports” on the warfarin interaction so the INR drop is not stated as an unqualified fact.

Issues 27/09/2026 10:38

  1. 1.1 / 1.3 — Vitamin interaction wording: The fat-soluble vitamin bullet (QRS line 550) says “not toxic at food doses,” but the ER (line 242) says a higher vitamin exposure and “not a toxic interaction at food doses.”

Fixes 27/09/2026 10:38

  1. 1.1 / 1.3 — Vitamin interaction wording: Replaced “not toxic at food doses” with “higher vitamin exposure, not a toxic interaction at food doses” on the fat-soluble vitamin interaction, matching the ER consequence.

Issues 27/09/2026 10:26

  1. 2.7 — Postprandial jargon: Benefits (line 525) says “Postprandial response when butter is replaced.” The ER glosses that word as “(after-meal),” and the sheet keeps the jargon with no plain-language term.
  2. 4.5 — Exceeds one A4 page: Protocol subs (lines 450–472), six multi-clause interactions (lines 547–552), eight biomarker rows (lines 590–677), the cadence (line 682), and four qualitative items (lines 691–700) are not condensed to a one-page budget.
  3. 7.5 — Pigment uptake jargon: At a glance (line 433) says “salad pigment uptake.” “Uptake” is a clinical-register word for absorption; the ER Conclusion says “absorption of vegetable pigments.”

Fixes 27/09/2026 10:26

  1. 2.7 — Postprandial jargon: Replaced the medium benefit “Postprandial response when butter is replaced” with “After-meal response when butter is replaced,” using the ER’s plain-language gloss.
  2. 4.5 — One-page condensation: Shortened the at-a-glance, protocol subs, three interaction lines, the monitoring cadence, and the qualitative items so those blocks take fewer lines. Required markers, interactions, and benefit facts were kept.
  3. 7.5 — Pigment uptake jargon: Replaced “salad pigment uptake” with “salad pigment absorption” in the at-a-glance, matching the ER Conclusion’s wording.

Issues 27/09/2026 10:07

  1. 1.3 — Plant-sterol monitor dropped: The plant-sterol interaction (line 551) omits the ER’s lead word “Monitor”, so the bullet only says the combined effect is unquantified and not known to be harmful.
  2. 4.5 — Over one A4 page: The 16px lede (line 433), six long interaction bullets (lines 547–552), eight monitoring rows (lines 590–678), and four qualitative items are not condensed to one A4 page.
  3. 9.4 — Mechanistic interaction clauses: The vitamin bullet (line 550) keeps “a fat-containing meal can increase absorption”, and the vitamin K bullet (line 547) spells out “the international normalized ratio” instead of the key fact alone.

Fixes 27/09/2026 10:07

  1. 1.3 — Plant-sterol monitor restored: Added “monitor” to the plant-sterol interaction so the item states the ER’s monitoring stance, not only that the combined effect is unquantified and not known to be harmful.
  2. 4.5 / 9.4 — Interaction bullets shortened: Vitamin K now says “INR (a clotting test)” instead of the spelled-out ratio, and the fat-soluble vitamin bullet no longer states the absorption mechanism. Drug parentheticals and the non-toxicity limit stay.

Issues 27/09/2026 09:52

  1. 2.15 — Lay clotting-test wording: Key Interactions (line 547) says avocado fruit “lowered the clotting test,” a consumer gloss, instead of the ER’s formal term international normalized ratio (INR).

Fixes 27/09/2026 09:52

  1. 2.15 — Lay clotting-test wording: Replaced “lowered the clotting test” with “lowered the international normalized ratio (INR, a clotting test)” in the warfarin interaction.

Issues 27/09/2026 09:37

  1. 1.1 / 1.3 — Higher absorption wording: The fat-soluble vitamin interaction (QRS line 550) says “higher absorption at high doses.” The ER (line 242) says a fat-containing meal can increase absorption, to monitor at high doses, and that the consequence is a higher vitamin exposure, not a toxic interaction at food doses.
  2. 1.1 / 1.2 / 1.3 — Toxicity hedge dropped: The olive-oil interaction (QRS line 552) says “no pharmacologic toxicity.” The ER (line 246) says “No pharmacologic toxicity from using both as foods is described.”

Fixes 27/09/2026 09:37

  1. 1.1 / 1.3 — Higher absorption wording: Changed the fat-soluble vitamin interaction from “higher absorption at high doses” to “monitor at high doses; a fat-containing meal can increase absorption,” and kept “not a toxic interaction at food doses.”
  2. 1.1 / 1.2 / 1.3 — Toxicity hedge restored: Changed the olive-oil interaction from “no pharmacologic toxicity” to “no pharmacologic toxicity from using both as foods is described.”

Issues 27/09/2026 09:23

  1. 1.1 / 1.3 / 7.2 / 7.4 — Pigment claim merged: The at-a-glance at line 433 says one butter-replacement meal showed pigment absorption from salad. The ER conclusion (lines 371–373) keeps that result as a separate feeding study, so the meal claim is strengthened.
  2. 1.1 — Allergy history wording: Qualitative item 4 at line 700 says “after intake with an avocado or latex history.” The ER (line 355) says “after intake in anyone with an avocado or latex history.”
  3. 7.5 — Oxidized in lede: Line 433 uses “oxidized,” which needs specialist knowledge. The plain word in the ER monitoring section is “rancid” (line 337).
  4. 9.4 — Case-report study detail: The warfarin interaction at line 547 includes “in case reports,” a study detail that item 9.4 says to strip.

Fixes 27/09/2026 09:23

  1. 1.1 / 1.3 / 7.2 / 7.4 — Pigment claim merged: Split the at-a-glance so salad pigment uptake is a separate meal, not a result of the butter-replacement meal. “Cholesterol linked to artery disease” became “artery-risk cholesterol” so the lede stays within 70 words.
  2. 1.1 — Allergy history wording: Qualitative item 4 now says symptoms occur after intake in anyone with an avocado or latex history, matching the ER.
  3. 7.5 — Oxidized in lede: Replaced “oxidized” with “rancid” in the at-a-glance.
  4. 9.4 — Case-report study detail: Removed “in case reports” from the warfarin interaction, leaving the clotting-test fact and that the oil was not studied.